These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24410431)

  • 1. Antiangiogenic agents in natural products for the treatment of gynecologic disorders.
    Aghamohammadi A; Hosseinimehr SJ
    Nutr Cancer; 2014; 66(2):206-13. PubMed ID: 24410431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic phytochemicals and medicinal herbs.
    Jeong SJ; Koh W; Lee EO; Lee HJ; Lee HJ; Bae H; Lü J; Kim SH
    Phytother Res; 2011 Jan; 25(1):1-10. PubMed ID: 20564543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.
    Frumovitz M; Sood AK
    Gynecol Oncol; 2007 Mar; 104(3):768-78. PubMed ID: 17306693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
    Song G; Li Y; Jiang G
    Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
    Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
    Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling.
    Huang S; Yang N; Liu Y; Hu L; Zhao J; Gao J; Li Y; Li C; Zhang X; Huang T
    Nutr Res; 2012 Jul; 32(7):530-6. PubMed ID: 22901561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotherapeutics from natural products: from bench to clinics?
    Bernas G
    Clin Hemorheol Microcirc; 2003; 29(3-4):199-203. PubMed ID: 14724342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF as a key mediator of angiogenesis in cancer.
    Carmeliet P
    Oncology; 2005; 69 Suppl 3():4-10. PubMed ID: 16301830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
    Limaverde-Sousa G; Sternberg C; Ferreira CG
    Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel Antiangiogenic Marine Natural Product Scaffolds.
    Ebrahim HY; El Sayed KA
    Mar Drugs; 2016 Mar; 14(3):. PubMed ID: 26978377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis.
    Ricci AG; Olivares CN; Bilotas MA; Meresman GF; Barañao RI
    Reprod Sci; 2011 Jul; 18(7):614-22. PubMed ID: 21266664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of angiogenesis inhibitors in tumour treatment.
    Fayette J; Soria JC; Armand JP
    Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.